Methoxyetomidate
Appearance
From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
| Clinical data | |
|---|---|
| Other names | ET-26 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C15H18N2O3 |
| Molar mass | 274.320 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Methoxyetomidate is an investigational anesthetic agent being developed by Jinzhou Ahon Pharmaceutical Co., Ltd. It is a short-acting intravenous anesthetic that acts as a positive allosteric modulator of GABAA receptors.[1] [2] As of 2024, methoxyetomidate is undergoing Phase 3 clinical trials for use in anesthesia.[3] [1]
References
[edit ]- ^ a b "ET-26 Methoxyetomidate Hydrochloride Development Information". Synapse by Patsnap. Retrieved 2024年11月23日.
- ^ Wang B, Chen S, Yang J, Yang L, Liu J, Zhang W (2017). "ET-26 hydrochloride (ET-26 HCl) has similar hemodynamic stability to that of etomidate in normal and uncontrolled hemorrhagic shock (UHS) rats". PLOS ONE. 12 (8) e0183439. Bibcode:2017PLoSO..1283439W. doi:10.1371/journal.pone.0183439 . PMC 5557577 . PMID 28813523.
- ^ "ET-26 Clinical Trials Overview". Synapse by Patsnap. Retrieved 2024年11月23日.
Stub icon
This pharmacology-related article is a stub. You can help Wikipedia by expanding it.